Forte Biosciences Inc (FBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$76.990.00%
Close 2026-08-28 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FBRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -0.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
FBRX — officer change
Dated 2026-08-27
Director: The entire board and officer team were replaced as a direct result of a merger transaction, which is a structural change rather than a voluntary executive departure or routine election.
Why it matters: More equity offerings may show ongoing cash needs. This can change how investors feel.
Worry ifA new equity offering is announced to raise money.
Less concerning ifThey did not announce new equity offerings. This shows they manage cash well.
Why it matters: Earnings results will show the company's financial health and cash use.
Watch forThe earnings report shows less cash use or better financial numbers.
Also watch forThe earnings report shows more cash use or worse financial numbers.
Why it matters: Watching cash reserves shows how well the company handles money. This affects trials and operations.
Watch forCash reserves rise a lot from the $58.2 million reported in Q1 2026 after the offering.
Also watch forCash reserves drop a lot or stay low after the offering.
Why it matters: More stock offerings may show ongoing money problems and hurt investor trust.
Worry ifA new stock offering is announced for over 5 million shares.
Less concerning ifNo new equity offerings announced in the next quarter.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$211 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $847 loss on $10,000 · 8.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,590 loss on $10,000 · 55.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Controlling expenses is crucial for managing cash burn. A decline would show effective cost management.
Supportive ifOperating costs are lower than last quarter.
Worry ifOperating costs go up again, increasing cash burn.
Why it matters: These results will help prove that FB102 works for treating vitiligo. Good results could help future work.
Supportive ifThe FB102 vitiligo study shows better FVASI scores. The results are positive.
Worry ifThe results show no clear improvement in FVASI scores.
Why it matters: Good results would support FB102's effectiveness. This would help its chances for commercialization.
Supportive ifTop results show a big improvement in patients with vitiligo.
Worry ifResults show no significant improvement. They also do not meet primary goals.
Why it matters: Progress in clinical trials is key for future growth. Positive updates could boost investor confidence.
Supportive ifThey announced good results from trials on microbiome therapies.
Worry ifDelays or failures in clinical trials are announced.
Why it matters: The acquisition could unlock the full potential of FB102 and accelerate its development. This is a key growth milestone for Forte.
Supportive ifThe acquisition will close in Q3 2026. All usual conditions will be met.
Worry ifThe acquisition does not close. This is due to unmet conditions or regulatory issues.
Why it matters: Watching cash burn will show how well the company manages costs as R&D rises.
Worry ifOperating losses are lower than in Q1 2026. This shows better cost control.
Less concerning ifOperating losses are higher than in Q1 2026. This shows rising cash burn.
Why it matters: Increasing losses signal that the company is struggling to control expenses. This could impact future funding needs.
Worry ifQ2 operating losses reported worse than $22.4M.
Less concerning ifQ2 operating losses were better than $22.4M.
Why it matters: The results will show if FB102 can treat celiac disease. This could help it reach more people.
Supportive ifTopline results from the Phase 2 celiac disease study are out. They show a strong improvement.
Worry ifResults show no strong improvement in the Phase 2 celiac disease study.
Why it matters: Good results could prove FB102 works for more autoimmune diseases.
Supportive ifTopline results from the Phase 1b alopecia areata trial are out. They show a strong improvement.
Worry ifResults from the Phase 1b alopecia areata trial show no strong improvement.